Compare Solaredge Technologies Inc (SEDG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Solaredge Technologies Inc vs BIO-TECHNE Corp — how do they compare? Solaredge Technologies Inc trades at $35.2 (market cap $2.24B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: BIO-TECHNE Corp is far larger — about 5.1× Solaredge Technologies Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals.
| SEDG | TECH | |
|---|---|---|
Market Cap | $2.24B | $11.34B |
Sector | Technology | Health |
52-Week High | $78.51 | $72.48 |
52-Week Low | $28.47 | $43.31 |
Enterprise Value | $2.10B | $11.36B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SolarEdge Technologies (SEDG) trades at $36.43, up 6.52% with a bullish technical signal despite negative profitability metrics. The stock shows mixed earnings performance with recent beats but faces significant challenges including a -20.29% net income margin and negative ROE. Recent news highlights collaboration with Infineon for AI data center technology and positive analyst upgrades from UBS citing 40% upside potential.
The outlook remains challenging with persistent losses and high debt levels, though recent technical strength and AI infrastructure developments offer potential catalysts. Key risks include execution challenges, policy dependency, and competitive pressures in the solar sector. Analyst consensus is mixed with 23% buy ratings but a $36.13 price target slightly below current levels.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
